CSL Limited Annual Report 2022/23 58 9 Social Social investment CSL’s approach to community support is guided by our Code of Responsible Business Practice and supplemented by our Global Community Contributions Policy. The policy applies to all CSL businesses and employees and is intended to be implemented to guide decision making and management of any form of community contribution, financial or by other means. The core of the policy is our community contributions framework, which sets out our key focus areas of support: patient communities, innovation and science and local communities. In 2022/23, CSL contributed US$42.6 million to support global efforts where we operate. 53% 46% to patient communities to innovation and science 1% to local communities US$42.6 million in community contributions* Sub focus areas *Does not include CSL Vifor. • Enhancing quality of life for patients in the conditions our therapies treat. • Improving access to our biological medicines. • Advancing knowledge in medical and scientific communities. • Fostering the next generation of medical researchers. • Supporting community efforts where we live and work. • Supporting communities in times of emergency. In February 2023, a catastrophic earthquake struck the border of Turkey and Syria, the deadliest to hit the region in more than two decades. Tens of thousands of lives were lost, and many more people were left in need of medical services and humanitarian aid. To support relief efforts, and in keeping with our promise to human health, CSL and employees together contributed A$351,752 to humanitarian organisations. Of that amount, which includes employee receipt matching, more than A$290,000 was donated to the Emergency Action Alliance in Australia – a coalition of 15 humanitarian relief charities. Further, CSL affiliates in the region undertook a critical product donation of 5,000 IUs of TETAGAM® (Tetanus immunoglobulin) to local authorities to support healthcare needs as extensive rebuilding efforts continue. Together, CSL and employees support Turkey and Syria relief efforts Our ability to supply life-enhancing and often life-saving therapies is only made possible by ensuring a safe, quality and positive donor experience. All CSL Plasma centres operate to the highest standards for the management and care of plasma donors. CSL Plasma continues several strategies to reduce donor adverse events (AEs), including an initiative to support plasma donor hydration at all United States centres in which donors can access water, juice and snacks before or after the plasma donation procedure. Our focus remains to minimise overall AEs, especially among first-time donors. We have enhanced training for phlebotomy and medical staff associate roles across the collection centre network. We have also increased proactive donor education through traditional and digital channels to support donation and healthier lifestyles. Focusing on the safety of plasma donors
RkJQdWJsaXNoZXIy MjE2NDg3